VasopressinInjection, USP

Vial closure is not made with natural rubber latex
Formulated, filled, and finished in our US-based manufacturing facilities

	Pack NDC#	Strength	Supplied As	Shelf Pack	Vial Opening Size	Product Info	Availability
	Strength: 20 Units/mL Supplied As: 1 mL Single Dose Vial NDC#: 0517-1020-25	0517-1020-25	20 Units/mL	1 mL Single Dose Vial	25	13 mm	Product Label Full Prescribing Information Safety Data Sheet	Limited Availability
Shelf Pack 25 Availability Limited Availability Product Label Full Prescribing Information Safety Data Sheet Contains 5 mg/mL chlorobutanol as a preservative Wholesaler Numbers ABC 10264598 Cardinal 1652452 McKesson 1613744 Morris & Dickson 198762 Case Information Unit of Sale NDC 0517-1020-25 Order Size 25 Case Size 24 Case Per Tier 110 Locate Distributor Receive Availability Emails

View Our Sales and Return Policy

Contact Us

Request for Medical Information Request a Grant Investigator Initiated Study Request a Certificate of Analysis Expanded Access Policy

P: 800-645-1706
(8:00am–6pm Monday - Thursday and Friday 8:00am–4pm Eastern Time)
P: 800-734-9236
F: 610-650-0170

E: pv@americanregent.com

Adverse Drug Events (ADEs) may be reported to the FDA:
Phone: 1-800-FDA-1088
Web: www.fda.gov/medwatch
P: 888-354-4859

E: pqc@americanregent.com
P: 888-354-4855
(9am–5pm Eastern Time, Monday - Friday)

E: ma@americanregent.com

For drug information outside of normal business hours that cannot wait until the next day, please call:

P: 877-845-6371
American Regent, Inc.
5 Ramsey Road
Shirley, NY 11967

P: 631-924-4000
F: 631-924-1731

Find a Distributor

Please choose your preferred method of contact

By clicking Submit, you confirm that you accept our Privacy Policy and that you agree to your personal contact information being used to contact you and added to our database. If at any time you wish your personal information to be removed from the American Regent^® database, please submit a message request to corpcommunications@americanregent.com.

Vasopressin Injection, USP

For intravenous use. Dilute prior to administration.

INDICATIONS AND USAGE
Vasopressin injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS
Vasopressin injection is contraindicated in patients with known allergy or hypersensitivity to 8-L-arginine vasopressin or chlorobutanol.

WARNINGS AND PRECAUTIONS
Can worsen cardiac function.
Patients may experience reversible diabetes insipidus.

ADVERSE REACTIONS
The most common adverse reactions included decreased cardiac output, bradycardia, tachyarrhythmias, hyponatremia, and ischemia (coronary, mesenteric, skin, digital).

The following additional adverse reactions were identified:

Bleeding/lymphatic system disorders: Hemorrhagic shock, decreased platelets, intractable bleeding

Cardiac disorders: Right heart failure, atrial fibrillation, bradycardia, myocardial ischemia

Hepatobiliary: Increased bilirubin levels

Renal/urinary disorders: Acute renal insufficiency

Vascular disorders: Distal limb ischemia

DRUG INTERACTIONS
Hemodynamic monitoring is recommended; adjust the dose of vasopressin as needed.

USE IN SPECIFIC POPULATIONS
Pregnancy: May induce tonic uterine contractions.

Pediatric Use: Safety and effectiveness have not been established.

Geriatric Use: Dose selection for an elderly patient should be cautious.

For additional safety information, please see Full Prescribing Information.

You are encouraged to report adverse drug events to American Regent, Inc. at 1-800-734-9236 or to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088.